Leerink Partners analyst Joseph Schwartz lowered his price target on Amicus Therapeutics (NASDAQ: FOLD) to $21.00 (from $23.00) after management ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE